AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AbCellera Reports Q3 2026 Business Results
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
AbCellera to Present at Upcoming Investor Conferences in November 2026
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Trading Information
- Previous Close Price
- $11.62
- Day Range
- $11.06–11.83
- 52-Week Range
- $2.75–15.02
- Bid/Ask
- $11.31 / $11.60
- Shares Outstanding
- 326.62M
- Market Cap
- $3.75B
- Volume/Avg
- 3M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 51.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 562
- Website
- https://www.abcellera.com
Valuation
Metric | ABCL |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.53 |
Price/Sales | 51.93 |
Price/Cash Flow | — |
Price/Earnings
ABCL
Financial Strength
Metric | ABCL |
|---|---|
Quick Ratio | 11.80 |
Current Ratio | 12.43 |
Interest Coverage | — |
Quick Ratio
ABCL
Profitability
Metric | ABCL |
|---|---|
Return on Assets (Normalized) | −7.75% |
Return on Equity (Normalized) | −10.96% |
Return on Invested Capital (Normalized) | −11.07% |
Return on Assets
ABCL
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%FfLpn | LOCK|<D@sQ | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!%q<pp | LOCK|HWPj | $99B | |||
| Moderna Inc MRNA | LOCK|$ZnG#S? | LOCK|p@r | $90B | |||
| argenx SE ADR ARGX | LOCK|!p#ScT | LOCK|?# | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|>G!%cb# | LOCK|l%n | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?^RL?#c | LOCK|vV^P | $31B | |||
| Incyte Corp INCY | LOCK|$CFY^b | LOCK|#d | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%LvyqP? | LOCK|sG$W | $22B | |||
| BioNTech SE ADR BNTX | LOCK|@$h<b^ | LOCK|Sh | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|L^!qRV | LOCK|dz | $16B |
United States